RecruitingNot ApplicableNCT06911970

Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment

Acute Effect of Moderate and High-Intensity Aerobic Exercise on the Anticancer Immune Response in Individuals Undergoing Treatment for Curable Cancer


Sponsor

Université de Sherbrooke

Enrollment

44 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Summary

The goal of this clinical trial is to determine to what extent anticancer immune cells mobilized by aerobic exercise exhibit migratory and functional capacity towards cancer cells in patients undergoing treatment for breast or colorectal cancer. The main questions it aims to answer are: • Do anticancer immune cells mobilized by aerobic exercise will display migratory and functional capacity in patients undergoing treatment for curable breast or colorectal cancer? Hypothesis: exercise will promote cell migration and these cells will display anti-cancer functional characteristics, suggesting a possible adjuvant and immunotherapeutic use of exercise. • Do the magnitude of this anti-cancer immune response to exercise depend on the intensity of exercise? Hypothesis: the achievement of a higher intensity of effort will enable greater mobilization of the cytotoxic lymphocytes of interest, but also the expression of markers predicting a more interesting adjuvant potential to immunotherapy. Researchers will compare the effect of two exercise sessions, one moderate-intensity continuous exercise session (MOD) and one high-intensity interval exercise (HIIE) on the migration and anticancer potentials of mobilized immune cells. Individuals aged between 40 and 70 with curable colon or breast cancer will be recruited to carry out a cross-over study with two experimental conditions. After a preliminary assessment visit, they will take part in: * Two familiarization visits to validate the exercise prescription * Two experimental visits (HIIE and MOD). During these conditions, blood samples will be taken before, after and 1 hour after the end of exercise to collect immune cells in the blood. At the end of the visits, participants will leave with an accelerometer to wear for three days depending on conditions, and a notebook containing a questionnaire to assess fatigue levels over the same three days.


Eligibility

Min Age: 40 YearsMax Age: 70 Years

Inclusion Criteria5

  • Diagnosis of non-metastatic breast or colon cancer
  • Age between 40 and 70
  • Have started chemotherapy or immunotherapy treatment and have at least three treatments remaining in the cycle
  • ECOG stage 0 to 1
  • Be able to perform moderate-intensity aerobic exercise (MOD) or EPI type cycling according to the established prescription and without experiencing pain in connection with the bicycle saddle

Exclusion Criteria4

  • Orthopedic, cardiac or metabolic limitation preventing safe aerobic exercise
  • Non-controlled health condition
  • Use of beta-blockers
  • Planned surgery during the study period.

Interventions

OTHERExercise

Moderate-Intensity Continuous Exercise (MOD): The MOD condition will consist of a 37-minute continuous aerobic exercise session on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 32-minute period at moderate intensity at a power corresponding to 50% of the last stop completed in the modified YMCA test completed in the preliminary visit. High-Intensity Interval Exercise (HIIE): The HIIE condition will consist of a 35-minute high-intensity aerobic exercise session on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (110% of power highest poweroutput reached during the submaximal test) and 2 minutes of active rest (25% of highest power output).


Locations(2)

Research Center on Aging

Sherbrooke, Quebec, Canada

Research Center on Aging

Sherbrooke, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06911970